24/7 Market News Snapshot 26 March, 2025 – Leap Therapeutics, Inc. Common Stock (NASDAQ:LPTX)

March 26, 2025

DENVER, Colo., 26 March, 2025 (247marketnews.com) – (NASDAQ:LPTX) are discussed in this article.
Leap Therapeutics, Inc. is experiencing significant momentum in the market, with shares opening at $0.619 and surging to $0.608—an impressive increase of 56.7% from its previous closing price of $0.388. This enthusiastic trading session has drawn considerable attention, evidenced by a robust trading volume of approximately 15.86 million shares, reflecting heightened investor interest and a potential turning point for the company.

Simultaneously, Leap has unveiled promising findings from its ongoing clinical trials concerning its lead therapy, sirexatamab (DKN-01), in the treatment of advanced colorectal cancer (CRC). Results from Part B of the Phase 2 DeFianCe study indicate that patients with elevated levels of DKK1 have benefitted from a statistically significant 32% increase in overall response rate (ORR). This outcome is accompanied by improved progression-free survival (PFS) and overall survival (OS) when compared to control groups.

The findings are particularly notable for patients who had not previously undergone anti-VEGF therapy, highlighting the effectiveness of this targeted approach. Leap’s advancements could position sirexatamab favorably within the sizable second-line CRC market.

Douglas E. Onsi, President and CEO of Leap, commented on the significance of these results, stating that they reinforce the company’s dedication to providing personalized cancer therapies. Plans are underway for a registrational Phase 3 clinical trial that will target patients showing promising biomarkers. Additionally, Leap is set to present data on FL-501 at the upcoming American Association for Cancer Research (AACR) Annual Meeting, demonstrating its commitment to advancing treatments for cachexia and other GDF-15 related diseases.

As Leap Therapeutics continues on this promising trajectory, the recent trial results and market performance signify a potential shift in cancer treatment paradigms, reinforcing the company’s vision of transforming oncology through innovative solutions.

Related news for (LPTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.